GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » Other Financing

SRPT (Sarepta Therapeutics) Other Financing : $0 Mil (TTM As of Sep. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics Other Financing?

Sarepta Therapeutics's Other Financing for the three months ended in Sep. 2024 was $0 Mil.

Sarepta Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 was $0 Mil.


Sarepta Therapeutics Other Financing Historical Data

The historical data trend for Sarepta Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Other Financing Chart

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.58 79.12 13.04 -71.66 -

Sarepta Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sarepta Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sarepta Therapeutics Other Financing Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics Business Description

Traded in Other Exchanges
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Executives
Ian Michael Estepan officer: Chief Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Michael Andrew Chambers director 215 FIRST STREET, CAMBRIDGE MA 02142
Bilal Arif officer: Chief Tech Ops Officer 215 FIRST STREET, CAMBRIDGE MA 02129
Ryan Edward Brown officer: SVP, General Counsel 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Kathryn Jean Boor director 3736 S. MAIN STREET, MARION NY 14505
Wigzell Hans Lennart Rudolf director OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram director, officer: President & CEO 2525 DUPONT DR, IRVINE CA 92612
Louise Rodino-klapac officer: Chief Scientific Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens director 6701 KAISER DRIVE, FREMONT CA 94555
Joseph Bratica officer: Principal Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton officer: SVP, General Counsel VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Sandesh Mahatme officer: Senior Vice President, CFO C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901